Список литературы к главе 10

1. Hiroyuki Kuwano, Yasumasa Nishimura, Tsuneo Oyamaetal. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society // Esophagus. 2015. Vol. 12. P. 1–30.

2. Hulscher J.B., Tijssen J.G., Obertop H., van Lanschot J.J. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis // Ann. Thorac. Surg. 2001. Vol. 72, N 1. P. 306–313.

3. Altorki N., Kent M., Ferrara C., Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus // Ann. Surg. 2002. Vol. 236, N 2. P. 177–183.

4. Kelsen D.P., Winter K.A., Gunderson L.L. et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer // J. Clin. Oncol. 2007. Vol. 25, N 24. P. 3719–3725.

5. Almhanna K., Strosberg J.R. Multimodality approach for locally advanced esophageal cancer // World J. Gastroenterol. 2012. Vol. 18, N 40. P. 5679–5687.

6. Peyre C.G., Hagen J.A., DeMeester S.R. et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes // Ann. Surg. 2008. Vol. 248, N 6. P. 979–985.

7. Давыдов М.И., Бохян В.Ю., Стилиди И.С. и др. Внутриплевральная толстокишечная пластика в хирургии рака грудного отдела пищевода // Сибирский онкологический журнал. 2004. Т. 2–3, № 10–11. С. 48–54.

8. Campbell N.P., Villaflor V.M. Neoadjuvant treatment of esophageal cancer //World J. Gastroenterol. 2010. Vol. 16, N 30. P. 3793–3803.

9. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial // Lancet. 2002. Vol. 359, N 9319. P. 1727–1733.

10. Allum W.H., Stenning S.P., Bancewicz J. et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer // J. Clin. Oncol. 2009. Vol. 27. P. 5062–5067.

11. Ronan J.K. Emerging Multimodality Approaches toTreat Localized Esophageal Cancer // JNCCN Journal of the National Comprehensive Cancer Network. 2019. Vol. 17, N 8. Р. 1009–1014.

12. Kelsen D.P., Ginsberg R., Pajak T.F. et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer // N. Engl. J. Med. 1998. Vol. 339. P. 1979–1984.

13. Alderson D., Cunningham D., Nankivell M. et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial // Lancet Oncol. 2017.Vol. 18, № 9. P. 1249–1260.

14. Boonstra J.J., Kok T.C., Wijnhoven B.P. et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial // BMC Cancer. 2011. Vol. 11. P. 181.

15. Cunningham D., Stenning S., Smyth E. et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03). Primary analysis results of a multicentre, open-label, randomised phase 2–3 trial // Lancet Oncol. 2017. Vol. 18, N 3. P. 357–370.

16. Urschel J.D., Vasan H., Blewett C.J. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer // Am. J. Surg. 2002. Vol. 183, N 3. P. 274–279.

17. Malthaner R., Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer // Cochrane Database Syst. Rev. 2003. Vol. 4. CD001556.

18. Hirao M., Ando N., Tsujinaka T. et al. Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications // Br. J. Surg. 2011. Vol. 98. P. 1735–1741.

19. Sjoquist K.M., Burmeister B.H., Smithers B.M. et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectableoesophageal carcinoma: an updated meta-analysis // Lancet Oncol. 2011. Vol. 12, N 7. P. 681–692.

20. Xiao-Hua Xu, Xue-Hong Peng, Ping Yu. et al. Neoadjuvant chemotherapy for resectable esophageal carcinoma: a meta-analysis of randomized clinical trials Asian Pacific // J. Cancer Prev. 2012. Vol. 13. P. 103–110.

21. Yoshifumi Baba, Masayuki Watanabe, Naoya Yoshida, Hideo Baba. Neoadjuvant treatment for esophageal squamous cell carcinoma // World J. Gastrointest. Oncol. 2014. Vol. 6, N 5. P. 121–128.

22. Nakamura K., Kato K., Igaki H. et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study) // Jpn. J. Clin. Oncol. 2013. Vol. 43. P. 752–755.

23. Hara H., Tahara M., Daiko H. et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma // Cancer Sci. 2013. Vol. 104. P. 1455–1460.

24. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Esophageal Cancers and Esophagogastric Junction. Version 5. 2020.

25. Минимальные клинические рекомендации европейского общества медицинской онкологии (ESMO). / Под ред. проф. С.А. Тюляндин, к.м.н. Д.А. Носов, проф. Н.И. Переводчикова. Москва : Издательская группа РОНЦ им. Н.Н. Блохина РАМН, 2010. 436 с.

26. European Society for Medical Oncology: clinical practice guidelines, in Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.2018: Annals of Oncology.

27. Almhanna K., Shridhar R., Meredith K.L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care? // Cancer Control. 2013. Vol. 20, N 2. Р. 89–96.

28. Arnott S.J., Duncan W., Gignoux M. et al. Preoperative radiotherapy for esophageal carcinoma // Cochrane Database Syst. Rev. 2005.

29. Schwer A.L., Ballonoff A., McCammon R. et al. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study // Int. J. Radiat. Oncol. Biol. Phys. 2009. Vol. 73. P. 449–455.

30. Yaping Xu, Xinmin Yu, Qixun Chen, Weimin Mao. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? // World Journal of Surgical Oncology. 2012. Vol. 10, N 173. Р. 1–8.

31. Tai P., Yu Е. Esophageal cancer management controversies: Radiation oncology point of view // World J. Gastrointest. Oncol. 2014. Vol. 6, N 8. P. 263–274.

32. Gebski V., Burmeister B., Smithers B.M. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis // Lancet Oncol. 2007. Vol. 8, N 3. P. 226–234.

33. Nygaard K., Hagen S., Hansen H.S. et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer // World J. Surg. 1992. Vol. 16, N 6. P. 1104–1110.

34. Apinop C., Puttisak P., Preecha N. A prospective study of combined therapy in esophageal cancer // Hepatogastroenterology. 1994. Vol. 41, N 4. P. 391–393.

35. Bosset J.F., Gignoux M., Triboulet J.P. et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus // N. Engl. J. Med. 1997. Vol. 337, N 3. P. 161–167.

36. Walsh T.N., Noonan N., Hollywood D. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma // N. Engl. J. Med. 1996. Vol. 335, N 7. P. 462–467.

37. Tepper J., Krasna M.J., Niedzwiecki D. et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 // J. Clin. Oncol. 2008. Vol. 26, N 7. P. 1086–1092.

38. Lv J., Cao X.F., Zhu B. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma // World J. Gastroenterol. 2010. Vol. 16, N 13. P. 1649–1654.

39. Gaast A.V., van Hagen P., Hulshof M. et al. Esophagogastric junction cancer: results from a multicenter randomized phase III study // J.Clin. Oncol. 2010. Vol. 28. P. 4004.

40. van Hagen P., Hulshof M.C., van Lanschot J.J. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer // N. Engl. J. Med. 2012. Vol. 366. P. 2074–2084.

41. Siddiqui F.A., Atkins K.M., Diggs B.S. et al. Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer // J. Gastrointest. Oncol. 2014. Vol. 5, N 2. P. 86–91.

42. Urba S.G., Orringer M.B., Turrisi A. et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma // J. Clin. Oncol. 2001. Vol. 19, N. 2. P. 305–313.